Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

Jul 13, 2006Journal of the American Academy of Child and Adolescent Psychiatry

Effectiveness and safety of extended-release dexmethylphenidate capsules in children with ADHD

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

d-MPH-ER significantly improved ADHD symptoms in 67.3% of pediatric patients compared to 13.3% for placebo.

The study involved 97 pediatric patients aged 6-17 with attention-deficit/hyperactivity disorder (ADHD).
Patients receiving d-MPH-ER showed a significant change in ADHD symptoms measured by the Conners ADHD/DSM-IV Scale (p < 0.001).
49.1% of those on d-MPH-ER reported adverse events suspected to be drug-related, compared to 25.5% on placebo.
The findings suggest that d-MPH-ER may be a more effective treatment option for ADHD than placebo.

AI simplified

OBJECTIVE: The efficacy and safety of dexmethylphenidate extended release (d-MPH-ER) was compared to placebo in pediatric patients with attention-deficit/hyperactivity disorder (ADHD).

METHOD: This multicenter, randomized, double-blind, placebo-controlled, parallel-group, two-phase study included 97 patients (ages 6-17 years) with DSM-IV-defined ADHD. The study was carried out between 2001 and 2003. After a 2-week evaluation phase, patients were randomized to d-MPH-ER or placebo for 7 weeks. Flexible d-MPH-ER dosing (30 mg/day) was permitted for 5 weeks, then patients remained on their optimal dose during the last 2 study weeks. The primary efficacy measure was change from baseline to final rating in Conners ADHD/DSM-IV Scale-Teacher version (CADS-T) total subscale score. Secondary efficacy variables included changes from baseline to final visit in CADS-T Inattentive and Hyperactive-Impulsive subscale scores, CADS-P DSM-IV total subscale score and Inattentive and Hyperactive-Impulsive subscale scores, Clinical Global Impressions-Improvement (CGI-I) and CGI-Severity (CGI-S) scale scores, and Child Health Questionnaire Parent Form 50 scores.

RESULTS: d-MPH-ER improved CADS-T total scores significantly compared with placebo (p <.001), and 67.3% of d-MPH-ER patients were rated much improved or very much improved on CGI-I at final visit versus 13.3% of placebo patients (p <.001). More patients taking d-MPH-ER (49.1%) than placebo (25.5%) spontaneously reported adverse events suspected as drug related.

CONCLUSIONS: Once-daily d-MPH-ER was more effective than placebo in the treatment of ADHD in children and adolescents.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief